// App-Quantinova.ai

4527 : Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Researchers

Presenter

  • Archana Anantharaman

Principal Investigators

  • Terence W. Friedlander

  • David Lu

  • Rachel Krupa

  • Gayatri Premasekharan

  • Jeffrey Hough

  • Matthew Edwards

  • Ryon Graf

  • Adam Jendrisak

  • Jessica Louw

  • Lyndsey Dugan

  • Dena C. Marrinucci

  • Ryan Vance Dittamore

  • Pamela Paris

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • Epic Sciences, Inc., San Diego, CA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Epic Sciences, Inc., San Diego, CA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved